MDxHealth Reports Flat Q3 Revenue and Suspends Full-Year 2026 Guidance

Key Facts

1MDxHealth expects Q3 2026 revenue of approximately $22.7 million, flat compared to the same period in 2025.

2The company suspended its full-year 2026 revenue guidance which was previously set at $110–115 million.

MDxHealth expects to report preliminary third-quarter 2026 revenue of approximately $22.7 million, remaining flat compared to the same period last year. The company stated in a release via GlobeNewswire that it has suspended its full-year 2026 revenue guidance, which was previously projected to be between $110 million and $115 million.

The suspension follows the exclusion of the Resolve mdx business as a discontinued operation, impacting the company's prior annual financial targets. Regarding market performance, MDXH closed at $0.6317 on October 14, 2026, after reaching a session low of $0.63 during the same day.